AI in the Pharmaceutical Industry: Innovations, Applications, and Challenges

Artificial Intelligence (AI) is increasingly transforming the pharmaceutical industry by streamlining processes across drug discovery, clinical development, manufacturing, and post-marketing surveillance. In drug discovery, platforms such as DeepMind’s AlphaFold enable accurate protein structure prediction and identification of promising drug candidates, thereby reducing timelines and costs traditionally associated with early-stage research. Clinical trials benefit from AI-driven predictive modeling, which improves patient recruitment, optimizes trial design, and enhances real-time monitoring through wearable devices and IoT sensors, ultimately increasing efficiency and success rates. In manufacturing and supply chain management, AI supports advanced forecasting, automation, and blockchain-based traceability, reducing waste and mitigating risks of counterfeit drugs. Personalized medicine is strengthened by AI tools that analyze genomic and clinical data to generate individualized treatment plans, improving therapeutic outcomes while minimizing adverse effects. Despite these advances, challenges remain in ensuring data quality, algorithmic transparency, regulatory compliance, and ethical governance. Regulatory agencies such as the FDA and EMA emphasize the need for explainable and validated AI models before widespread adoption. This review critically evaluates the innovations and limitations of AI in the pharmaceutical sector, highlighting its potential to improve healthcare delivery while underscoring the importance of rigorous validation and regulatory oversight.

Artificial Intelligence, Drug Discovery

1. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773–780. doi:10.1016/j.drudis.2018.11.014. [Google Scholar] [Crossref]

2. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7. [Google Scholar] [Crossref]

3. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31–38. doi:10.1038/s41591-021-01627-9. [Google Scholar] [Crossref]

4. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477. doi:10.1038/s41573-019-0024-x. [Google Scholar] [Crossref]

5. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–1250. doi:10.1016/j.drudis.2018.01.039. [Google Scholar] [Crossref]

6. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2. [Google Scholar] [Crossref]

7. Bender E. DeepMind’s AlphaFold AI predicts structures for nearly all human proteins. Nature. 2021;597(7876):509–510. doi:10.1038/d41586-021-02025-y. [Google Scholar] [Crossref]

8. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. doi:10.1038/s41591-018-0316-z. [Google Scholar] [Crossref]

9. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(4):e1312. doi:10.1002/widm.1312. [Google Scholar] [Crossref]

10. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Drug Development. Silver Spring (MD): FDA; 2023. Available from: https://www.fda.gov [Google Scholar] [Crossref]

11. European Medicines Agency. Reflection paper on the use of AI in medicinal product development. EMA/CHMP/ICH; 2023. Available from: https://www.ema.europa.eu [Google Scholar] [Crossref]

12. .International Council for Harmonisation. Guideline on general principles of artificial intelligence/machine learning in drug development. ICH; 2024. Available from: https://www.ich.org [Google Scholar] [Crossref]

13. Topol EJ. Individualized medicine from pre-womb to post-tomb. Cell. 2014;157(1):241–253. doi:10.1016/j.cell.2014.02.012. [Google Scholar] [Crossref]

14. Mullard A. IBM Watson Health’s struggles highlight challenges for AI in medicine. Nat Rev Drug Discov. 2022;21(3):171–172. doi:10.1038/d41573-022-00044-y. [Google Scholar] [Crossref]

15. 15.Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13. doi:10.1016/j.cell.2020.01.021. [Google Scholar] [Crossref]

16. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038–1040. doi:10.1038/s41587-019-0224-x. [Google Scholar] [Crossref]

17. Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604–610. doi:10.1038/nature25978. [Google Scholar] [Crossref]

18. Walters WP, Barzilay R. Applications of deep learning in molecule generation and molecular property prediction. Acc Chem Res. 2021;54(2):263–270. doi:10.1021/acs.accounts.0c00699. [Google Scholar] [Crossref]

19. Gomes J, Ramsundar B, Feinberg EN, et al. Molecular machine learning with DeepChem. J Chem Inf Model. 2017;57(8):1757–1772. doi:10.1021/acs.jcim.7b00237. [Google Scholar] [Crossref]

20. Altae-Tran H, Ramsundar B, Pappu AS, et al. Low data drug discovery with one-shot learning. ACS Cent Sci. 2017;3(4):283–293. doi:10.1021/acscentsci.6b00367. [Google Scholar] [Crossref]

21. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. Front Environ Sci. 2016;3:80. doi:10.3389/fenvs.2015.00080. [Google Scholar] [Crossref]

22. Gawehn E, Hiss JA, Schneider G. Deep learning in drug discovery. Mol Inform. 2016;35(1):3–14. doi:10.1002/minf.201501008. [Google Scholar] [Crossref]

23. Bate A, Luo Q, Pradhan M, et al. Artificial intelligence in clinical trial design and conduct. Clin Pharmacol Ther. 2021;109(4):831–844. doi:10.1002/cpt.2145. [Google Scholar] [Crossref]

24. Waring J, Lindvall C, Umeton R. Automated clinical trial eligibility screening: a systematic review. Lancet Digit Health. 2020;2(9):e486–e497. doi:10.1016/S2589-7500(20)30137-2. [Google Scholar] [Crossref]

25. Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine. Eur Heart J. 2019;40(25):2058–2073. doi:10.1093/eurheartj/ehz056. [Google Scholar] [Crossref]

26. Alsumidaie M. Artificial intelligence in clinical trials: patient recruitment and retention. Appl Clin Trials. 2019;28(5):32–36. [Google Scholar] [Crossref]

27. Lee J, Bagheri B, Kao HA. A cyber-physical systems architecture for Industry 4.0. Manuf Lett. 2015;3:18–23. doi:10.1016/j.mfglet.2014.12.001. [Google Scholar] [Crossref]

28. Leng J, Ruan G, Jiang P, et al. Blockchain empowered sustainable manufacturing. Renew Sustain Energy Rev. 2020;132:110112. doi:10.1016/j.rser.2020.110112. [Google Scholar] [Crossref]

29. Tao F, Qi Q, Liu A, Kusiak A. Data-driven smart manufacturing. J Manuf Syst. 2018;48:157–169. doi:10.1016/j.jmsy.2018.01.006. [Google Scholar] [Crossref]

30. Wang J, Ma Y, Zhang L, et al. Deep learning for smart manufacturing. J Manuf Syst. 2018;48:144–156. [Google Scholar] [Crossref]

31. Davenport T, Kalakota R. The potential for AI in healthcare. Future Healthc J. 2019;6(2):94–98. [Google Scholar] [Crossref]

32. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347–1358. [Google Scholar] [Crossref]

33. Beam AL, Kohane IS. Big data and machine learning in healthcare. JAMA. 2018;319(13):1317–1318. [Google Scholar] [Crossref]

34. Chen M, Hao Y, Cai Y, et al. AI in precision medicine. Comput Struct Biotechnol J. 2020;18:2851–2861. [Google Scholar] [Crossref]

35. Jiang F, Jiang Y, Zhi H, et al. AI in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230–243. [Google Scholar] [Crossref]

36. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719–731. [Google Scholar] [Crossref]

37. Brown AS, Patel CJ. Drug repositioning database. Sci Transl Med. 2017;9(316):eaal3239. [Google Scholar] [Crossref]

38. Li J, Zheng S, Chen B, et al. Computational drug repositioning. Brief Bioinform. 2016;17(1):2–12. [Google Scholar] [Crossref]

39. Himmelstein DS, Lizee A, Hessler C, et al. Drug repurposing via biomedical data. eLife. 2017;6:e26726. [Google Scholar] [Crossref]

40. Zhong RY, Xu X, Klotz E, Newman ST. Intelligent manufacturing. Engineering. 2017;3(5):616–630. [Google Scholar] [Crossref]

41. EMA. Good Manufacturing Practice guidelines. 2023. [Google Scholar] [Crossref]

42. FDA. CFR Title 21 Part 11. 2023. [Google Scholar] [Crossref]

43. Morris GM, Huey R, Lindstrom W, et al. AutoDock4. J Comput Chem. 2009;30(16):2785–2791. [Google Scholar] [Crossref]

44. Ramsundar B, Liu B, Wu Z, et al. DeepChem library. J Chem Inf Model. 2019;59(3):943–953. [Google Scholar] [Crossref]

45. Friesner RA, Banks JL, Murphy RB, et al. Glide docking. J Med Chem. 2004;47(7):1739–1749. [Google Scholar] [Crossref]

46. Ferrucci D. IBM Watson AI. AI Mag. 2012;33(1):59–79. [Google Scholar] [Crossref]

47. Harpaz R, DuMouchel W, LePendu P, et al. Pharmacovigilance signal detection. Clin Pharmacol Ther. 2013;93(6):539–546. [Google Scholar] [Crossref]

48. Botsis T, Nguyen MD, Woo EJ, et al. Text mining for adverse events. Pharmacoepidemiol Drug Saf. 2011;20(3):258–272. [Google Scholar] [Crossref]

49. Sarker A, Ginn R, Nikfarjam A, et al. Social media pharmacovigilance. J Biomed Inform. 2015;54:202–212. [Google Scholar] [Crossref]

50. Wang C, Liu M, Wang J, et al. NLP in pharmacovigilance. Drug Saf. 2019;42(7):743–757. [Google Scholar] [Crossref]

51. Trifirò G, Coloma PM, Rijnbeek PR, et al. Signal detection databases. Drug Saf. 2012;35(8):695–706. [Google Scholar] [Crossref]

52. EMA. EudraVigilance database. 2023. [Google Scholar] [Crossref]

53. FDA. FAERS database. 2023. [Google Scholar] [Crossref]

54. Bate A, Lindquist M, Edwards IR, et al. Bayesian neural network ADR detection. Eur J Clin Pharmacol. 1998;54(4):315–321. [Google Scholar] [Crossref]

• The Role of Artificial Intelligence in Revolutionizing Library Services in Nairobi: Ethical Implications and Future Trends in User Interaction
• ESPYREAL: A Mobile Based Multi-Currency Identifier for Visually Impaired Individuals Using Convolutional Neural Network
• Comparative Analysis of AI-Driven IoT-Based Smart Agriculture Platforms with Blockchain-Enabled Marketplaces
• AI-Based Dish Recommender System for Reducing Fruit Waste through Spoilage Detection and Ripeness Assessment
• SEA-TALK: An AI-Powered Voice Translator and Southeast Asian Dialects Recognition